List of Small Molecule Pharmaceuticals Companies in North Carolina - 65

Adroit Pharmaceutical Development was founded to efficiently identify new formulations and process technologies for our clients. We also work with clients to identify and correct problems with their existing formulations and processes.

Areteia Therapeutics is a clinical stage biotechnology company committed to putting respiratory patients in better control of their disease—and back in control of their lives. The company's purpose is to develop and deliver novel inflammation modulating therapies to improve the lives of patients with respiratory diseases. Areteia Therapeutics is dedicated to advancing the treatment of respiratory diseases, including asthma and eosinophilic asthma, through innovative research and development.

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.

At Arrivo, we strive to set a new standard in drug development that starts with the selection of drug candidates and runs throughout clinical development. Our approach and decision-making has delivered a history of excellent returns and product successes that makes us the trusted partner for industry and investors.

Ascletis is an innovative R&D driven biotech listed on Hong Kong Stock Exchange (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of NASH, cancer lipid metabolism and oral checkpoint inhibitors, viral hepatitis and HIV/AIDS for unmet medical needs in China and globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Gannex, a wholly-owned company of Ascletis, is fully dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets – FASN, THR-beta and FXR, and three combination therapies.

Avazyme, Inc. a contract research solution provider, offering field and laboratory testing, product development, and expert consulting services to the agriculture and food industries. Avazyme's comprehensive services include food safety analyses for contaminants, pathogens, allergens, food quality and nutrition analysis, genetic trait testing, product safety, FDA Menu Labeling, pesticide residues, mycotoxin analysis, specialized studies for regulatory submission data packages, and a full spectrum of testing for product safety and product quality related to Industrial Hemp. Avazyme provides fast and reliable answers to ensure product safety and high product quality for consumable food, feed, cosmetics, nutraceutical Avazyme also offers comprehensive laboratory and "​in-brewery"​ services to craft breweries and local hops growers and maltsters. Most recently, Volker and his Avazyme team have been a strong supporter and testing partner for the fast-emerging Industrial Hemp Industry in North Carolina and the entire East Coast

Avicenna Biosciences was founded to solve the intractable challenges that previously stopped drug candidates in their tracks. We have created an ML-driven medicinal chemistry platform that makes Lead Optimization faster, cheaper, and more successful – transforming sub-optimal development candidates into life-saving drugs. The platform has seen rapid success in discovering the first orally available, CNS-penetrant ROCK inhibitors for the treatment of neurodegenerative diseases, with IND-enabling studies initiated just one year since the program kicked off.

Bantam Pharmaceutical is a drug discovery company harnessing the power of mitochondrial dynamics to address unmet needs in oncology. Using its unique expertise in mitochondrial dynamics, Bantam is developing novel, first-in-class small molecule oral therapeutics for difficult-to-treat hematological and solid tumors. Bantam is currently pursuing an IND application for Its lead candidate, BTM-3566, in B-cell malignancies. About BTM-3566 BTM-3566 is an orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphomas (DLBCL). BTM-3566’s anti-cancer mechanism of action is unique from any other therapeutic, disrupting mitochondrial function in tumor cells to induce apoptosis (cell death). An IND application for BTM-3566 in B-cell malignancies is currently underway and will be completed by Q1 2022.

Belhaven Biopharma is developing a portfolio of dry powder nasal medicines to provide convenient, safe, and rapid treatments in emergency situations

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. We are a commercial-stage biotech company with US headquarters in Durham, North Carolina. Our European headquarters is in Dublin, Ireland, and our Discovery Center of Excellence is rooted in Birmingham, Alabama, with many other regional offices around the world. As world leaders in structure-guided drug design, we draw on the strengths and expertise of all our colleagues—from those of us in the field or behind the scenes in our labs, to others based in home offices and around the globe. To view our LinkedIn community guidelines, please visit bit.ly/BCRXGuidelines.

Biolink LifeSciences is a premier contract research organization offering a comprehensive range of services including synthesis, characterization, formulation development, and analytical services for small to large molecules for nearly all dosage forms. Our strength resides with our highly experienced team in synthetic chemistry, analytical method development & validation and formulation development to solve difficult problems.

Brii Biosciences is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice. Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline. Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.

Caeregen Therapeutics discovers and develops novel therapies which repair, restore, and protect damaged and diseased tissues by reactivating the pathways and signaling which accompany normal cellular and tissue development. Our revolutionary regenerative medicine approaches have the potential to restore lost or degraded functioning to diseased tissue and organs.

CAMAG is the world leader in High-Performance Thin-Layer Chromatography. We provide high-end instruments, tools and concepts for TLC/HPTLC. Additionally, we support our clients with training, technical and contract laboratory services. Wherever complex substance mixtures are analyzed (e.g. herbal, environmental or forensic samples), TLC/HPTLC often is an excellent alternative to GC and HPLC. Moreover, it has proven value as a solid quantitative analysis technique in quality assurance of food, pharmaceuticals and other industrial products. Since 1961, CAMAG is dedicated to the development and manufacturing of instruments, software and consumables for all steps of the TLC/HPTLC procedure. Our products are truly Swiss made and have an excellent reputation throughout the world.

At Chimerix, we are on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. With a focus in oncology, we are devoted to filling gaps in the treatment paradigm.

Cloud Pharmaceuticals is a pharmaceutical company that specializes in in silico therapeutics, revolutionizing drug discovery and development processes.

Collaborations Pharmaceuticals, Inc. works on drug discovery for rare and neglected diseases. We develop and license our AI software as well as provide fee for services for pharmaceutical and consumer product services. To date we have won with collaborators $23.5M in grants since 2016.

Concentrx Pharmaceuticals, Inc. Management Team; Gilbert S. Mott, Jr.; Eric C. Richardson; W. James Alexander

Dignify Therapeutics is a drug development company focused on delivering novel drug therapies for bladder and bowel disorders in spinal cord injured individuals.

Eldec Pharmaceuticals Inc. is a preclinical biotech company focused on developing novel peptide therapeutics to treat inflammatory and autoimmune diseases. The company was spun out of the University of North Carolina at Chapel Hill (UNC-CH) in 2017 and is currently developing peptide-based therapies to treat lung infections and lung inflammation.

Emergo Therapeutics: Bringing the Immune Response back into Balance

Evecxia is the first company dedicated to realizing the therapeutic potential of amplifying serotonin synthesis to treat brain disorders. Serotonin synthesis amplification is distinct from targeting serotonin transporters (e.g., SSRIs) and receptors (e.g., psilocybin). Evecxia deploys 5-HTP, the natural serotonin precursor, delivered via proprietary drug delivery technologies to achieve sustained serotonin synthesis amplification. Evecxia has two Phase 2 clinical-stage drug candidates in development. EVX-101 is being developed as an adjunctive treatment for depression when first-line SSRI/SNRI antidepressants alone are inadequate. EVX-301 is being developed as a rescue therapy for patients in acute suicidal ideation crisis. Evecxia holds a comprehensive portfolio of issued and pending patents on the 5-HTP sustained-release/serotonin amplification method, doses, formulations, and related technologies.

Exela Pharma Sciences LLC is a specialty pharmaceutical company based in Lenoir, North Carolina, founded in 2005. The company develops, manufactures, and markets both generic and proprietary sterile injectable and ophthalmic products. Exela aims to improve patient outcomes and reduce healthcare costs through its innovative offerings. With a workforce of 501–1,000 employees, Exela specializes in products that face high barriers to market entry, utilizing regulatory pathways like Abbreviated New Drug Approvals (ANDA) and 505(b)(2) submissions. The company focuses on delivering high-quality, affordable products that enhance the experiences of healthcare providers and patients, emphasizing ease of use and clinical effectiveness. Exela's product range includes sterile injectables designed for improved safety and faster preparation, as well as sterile ophthalmic solutions that meet strict regulatory standards. The company operates a vertically integrated model, managing development, manufacturing, and commercialization in-house, which supports its commitment to quality control and innovation in the pharmaceutical industry.

EydisBio is a small biotech startup based out of Durham, NC focusing on the development of a platform of small molecule therapeutics targeting a variety of diseases driven by aberrant inflammatory/autoimmune processes.

Fennec Pharmaceuticals is a biotechnology company focused on improving the lives of children with cancer by addressing chemotherapy-induced hearing loss.

Cisplatin and other platinum compounds are essential chemotherapeutic components for many pediatric malignancies. Unfortunately, platinum-based therapies can cause ototoxicity in many patients, leaving many survivors of childhood cancer with permanent and irreversible hearing loss. Permanent hearing loss, even minimal, acquired at a young age has a devastating impact on development, education, and socialization and a lifelong negative impact on Quality of Life. There are no currently approved treatments for the prevention of platinum-induced hearing loss. At Fennec Pharmaceuticals, we are dedicated to the development of our investigational agent, PEDMARK™, for the prevention of ototoxicity in children, and we hope that this will enable more children to retain their hearing. In honor of our namesake, the fennec fox, we strive to embody adaptability and resourcefulness in everything we do. Please see www.fennecpharma.com for more information.

Frontier Scientific Solutions (FSS) is a contract service organization (CSO) which supports the life science industry by offering cGMP temperature-controlled storage, distribution, and logistic services. Drug development and commercialization require continuous temperature monitoring and control. Frontier's diverse offerings protect product integrity throughout the pharmaceutical supply chain. FSSs' validated software, cGMP storage and drug distribution facility, industry expertise and stringent quality standards support this objective throughout packaging, storage and distribution.

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer.

Gilero offers end-to-end device design, development and contract manufacturing in the medical and pharmaceutical industries. Specializing in the areas of consumable and reusable medical devices, drug delivery, combination products and complex electromechanical systems, Gilero offers a wide range of services to meet your medical or drug delivery device needs.

Jellatech is a B2B biotech business based in Raleigh, NC producing human proteins for advancements in health using our unique cell-based technology. By unlocking the production of complex proteins at scale, Jellatech is enabling the creation of new possibilities for health and longevity, starting with Type I collagen. Jellatech’s mission is to revolutionize biomedical applications through cutting-edge, human-identical proteins. Jellatech enables advancements in tissue regeneration, injectable aesthetics, cell and gene therapy, and various therapeutic applications by supplying human-identical collagen and complex proteins. With all of it's known limitations, the tissue-extracted bovine and porcine medical grade collagen market for biomedical applications is expected to surpass $2.4B by 2032; however, with the introduction of a viable supply of human collagen across key verticals, the total addressable market (TAM) for human collagen alone could surpass $100-150 billion in the near future. Why Jellatech? Jellatech's platform is the only solution to deliver a reliable, consistent supply of bio-identical, fully functional human type I collagen for biomedical applications. Contact us to learn more. This is just the beginning. The potential is vast, and we’re here to help companies achieve breakthroughs in healthcare and beyond. Join us in unlocking a brighter future.

Great software in the right hands can change the world. We’ve seen it. You may have too. JMP products are behind many of the world’s greatest green-energy technologies, pharmaceutical breakthroughs, and high-tech improvements. For 30-plus years, JMP statistical software products have helped users see data clearly. It’s spelled J-M-P but pronounced “jump,” suggesting a leap in interactivity, a move in a new direction. Our purpose is to empower scientists and engineers via our statistical discovery software. Although our purpose is clearly connected to our software, it doesn’t end there. As an employer, JMP purposefully creates and maintains a culture of camaraderie that allows the personalities of our diverse and inclusive employee base to shine through. JMP is an equal opportunity employer. If you’re considering a career move, check out JMP Statistical Discovery. JMP employees live and work across the Americas, Europe, and Asia. Our business is growing, our employees are engaged, and our work is rewarding. JMP is a SAS company. Read more: www.jmp.com/about

Kinvard Bio is committed to developing a durable new class of antibiotics to treat the most challenging acute and chronic drug-resistant bacterial infections. Our chemistry platform technology is based on groundbreaking research that has been exclusively licensed from the Myers lab in the Department of Chemistry and Chemical Biology at Harvard University and funded by the Kineticos AMR Accelerator Fund I (KAMRA I). The oxepanoprolinamides (OPPs) represent a distinct class of lincosamide antibiotics that are pre-organized for highly effective and differentiated binding to the bacterial ribosome. In preclinical studies, OPPs have proven effective against both Gram-positive and Gram-negative bacterial pathogens associated with clinical needs that remain unmet.

KSE Scientific is a Bioprocess manufacturer specializing in the production of sterile products for the Tissue Banking, Pharmaceutical, and Biotech industries.

Kuria Therapeutics is a biopharmaceutical company that develops novel Nrf2 activators to treat blinding diseases.

Kymanox (‘ki-mah-noks'), meaning Ideal Knowledge Transfer, advances life science innovation through insightful solutions and collaboration. We do this by accelerating the design and commercialization of modern medicines for our customers using integrated engineering, scientific, compliance, and project management solutions that are insightful, collaborative, and comprehensive. By building and supporting the development of modern medicines, Kymanox has proven, end-to-end solutions that are helping bring better Life Science Products to the market- and keep it there. We do all of this with heart and pride… because patients deserve better. Kymanox, founded in 2004, serves clients from Fortune 100 companies to virtual start-up companies all across the globe. Headquartered in Research Triangle Park, NC, we have US offices in Boston and Philadelphia, and since 2022 have expanded to Germany, Switzerland, and Israel.

Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. Our proprietary PRINT technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. PRINT technology is a scalable cGMP compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. Liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. Liquidia is advancing product candidates from its own pipeline. These initial product candidates, LIQ861 and LIQ865, apply the PRINT technology to better drug delivery in inhaled and pain therapeutic areas, respectively. The PRINT technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.

Madera is the leader in highly potent and specific activators of the mitochondrial protease, ClpP. Together with our academic collaborators and the NIH/NCI, we have established the in vitro and in vivo performance of these agents. Notably, our agents provide a new mechanism of action that is effective on a number of drug-resistant cancer cells and patient-derived tissue samples. This technology is backed by the broadest patent portfolio in the area.

Marius Pharmaceuticals strives to better the lives of men and women by focusing on therapies designed for hypogonadism or Testosterone Deficiency. Our vision is to holistically improve metabolic health and mitigate significant unnecessary costs to the global healthcare system.

Marken is the clinical precision logistics and advanced therapy subsidiary of UPS Healthcare. The UPS Healthcare network consists of 200+ locations worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 46 locations worldwide, while maintaining the leading position for cell and gene therapy services, direct-to-patient and home healthcare services, biological sample shipments and biological kit production. Marken's dedicated 2,600+ staff members manage 200,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries and territories and have orchestrated 17,500+ home healthcare visits. Additional services such as ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken's unique position in the pharma and logistics industry. Delivering What Matters From Clinical to Commercial.

The global leader in continuous flow thermal sterilization. MTI Bioscience services the biotech, biopharmaceutical manufacturing, and biofuel industries for sterilization of growth media.

First in-class platform for harnessing the synergy between antibodies and mucus to reinforce the mucus barrier for mucosal health Proprietary intravaginal ring technologies for sustained delivery of small molecules to biomacromolecules Unparalleled safety from topical delivery

Nelum is a clinical stage biopharmaceutical company developing first in class and best in class patented molecules. Our area of focus is different forms of cancer. Our first drug, NLM-001, is a best in class small molecule hedgehog inhibitor currently in a phase Ib-IIa clinical trial in pancreatic cancer, after showing a safe profile in the Phase I trial.

Nitta Gelatin produces pharmaceutical and food-grade gelatin for a variety of uses in the pharmaceutical industry.

Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete’s foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Morrisville, North Carolina.

Small Molecules

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company developing and commercializing therapies for the treatment of eye disorders.

Parion Sciences is a development stage company dedicated to research, development, and commercialization of treatments to restore patient's innate mucosal surface defenses. In the eye and in the lung, our layer of protective mucus plays an important role in keeping our bodies healthy. Sometimes though, either through genetics, aging or environmental stimulus, our innate mucosal defense system can become compromised. Parion's science driven technologies target respiratory and ocular diseases in which the patient's ability to protect their mucosal surfaces is compromised.

Pathalys Pharma is a private, late-stage clinical biopharmaceutical company committed to the development of advanced therapeutics that address unmet needs in the management of late-stage chronic kidney disease (CKD). Pathalys was created in partnership with Catalys Pacific and DaVita to become a multi-asset pharmaceutical company focused on the needs of patients with end-stage renal disease

Small Molecules

The mission of PharmaLogika is to provide quality services and the highest level of expertise to start-up as well as established industry leaders from discovery, through clinical trials, to commercialization of ideas. Our goals include the deployment and management of consulting teams utilizing our online products, while maintaining the lowest possible overhead cost structures. Our target audience is primarily but certainly not exclusively small to medium size businesses within the Pharmaceutical, Biotech, and Medical Device industries.

We are a fully integrated pharmaceutical company located in Cranbury, engaged in developing and sales & marketing of generic pharmaceutical products in North American and South American markets. Since launching our first product, Benazepril in 2010, we have launched 11 products in U.S. market. Through reliable products’ quality, manufacturing capability and competitively strategic API resources from China, we have successfully reduced the medical cost for American buyers and help millions of patients against their illness.

Priovant Therapeutics is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the greatest morbidity and mortality. We are developing oral brepocitinib, a potential first-in-class dual inhibitor of TYK2 and JAK1, across multiple severe autoimmune indications, unlocking new treatment options for patients who are underserved by existing therapies.

Qualicaps manufactures empty two-piece capsules (gelatin and hypromellose) and encapsulation equipment under cGMP regulations for use by pharmaceutical, OTC and dietary-supplement manufacturers.

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.

We know the HPA-T Axis Sanesco Health International is a biomedical company providing licensed healthcare practitioners with innovative, evidence-based and clinically-effective solutions. Assessing, monitoring and correcting neurotransmitter and hormone imbalances is not just what we do, it's ALL we do. We believe in identifying the underlying root causes behind symptoms and conditions affecting HPA-T Axis function. We offer a specialized, clinical model to help health care practitioners see each patient holistically on a neuroendocrine level, and to guide their patients on a healthier path. Sanesco's Communication System Management clinical model includes: -non-invasive functional laboratory testing -personalized patient-centered reporting -all-natural nutritional formulas Our team's clinical expertise, on-staff clinician support, complimentary interpretations, education and hands-on training mean better results for practitioners and their patients. The reason why we choose to specialize in optimizing HPA-T Axis function is because of the pivotal role it plays in the body's Communication System as a whole. Upstream biochemical imbalances found in the critical messengers of this axis can contribute to the manifestation of cognitive function issues, mood disorders and other symptoms and conditions such as: depression, anxiety, insomnia or sleep concerns, Alzheimer's, dementia and memory loss, impairments of focus and attention, PTSD, weight issues, metabolic syndrome, blood sugar regulation, diabetes, chronic pain, fibromyalgia, chronic fatigue, sexual health, menopause, autism, ADD/ADHD, and addictions. Optimizing function of the HPA-T Axis has a positive effect on the rest of the neuroendocrine system and balancing the body's Communication System as a whole. This creates our clinical model which is key to addressing a plethora of symptoms and conditions, and optimizing health and overall quality of life. Privacy Policy https://sanescohealth.com/terms-privacy/

Scorpius Holdings Inc., through its Scorpius BioManufacturing subsidiary, is an integrated contract development and manufacturing organization dedicated to transparent collaboration and flexible, high-quality biologics. With an experienced team and new, purpose-built U.S. facilities, Scorpius Holdings Inc. is committed to excellence in large molecule cGMP manufacturing.

Sequence Inc. provides turn-key consulting solutions and services for the biopharmaceutical manufacturing industry with a focus on Commissioning, Qualification and Validation (CQV) and Digital Solutions for facilities, utilities, equipment, computerized systems and labs. Through a fully functional, mock pharmaceutical manufacturing training facility, consultants are trained in a hands-on environment that is unique in the industry that includes both equipment and software. Founded in 2002, Sequence provides consulting solutions to clients across the U.S. and parts of Europe. The company is headquartered in the heart of RTP in Morrisville, NC with a second hub in Framingham, MA.

Sterling Pharmaceutical Services LLC is a full-service pharmaceutical contract manufacturer and formulation development expert that specializes in technology transfers, scale-up, and commercial manufacturing.

T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D-959 and has initiated pre-clinical studies in Huntington’s Disease models.

Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need.

Triangle Insights Group is a strategy consulting firm that delivers high-impact solutions to clients in the life sciences industry.

Monoclonal Antibody

Vast is a preclinical airway immunology company focused on breaking the vicious cycle of infection and chronic inflammation in respiratory diseases. The Vast technology platform begins with the unmatched antimicrobial activity of nitric oxide in the form of stable prodrugs. When our new chemical entities are combined with inhalation formulation expertise and proprietary chemistry for delivering drug candidates to the lungs, the result is aerosolized therapies targeting the specific needs of individual patient populations. Nitric oxide is an endogenous molecule that plays a vital role in the natural immune system response to microbial pathogens. Taking cues from human physiology, our nitric oxide based “antibiotic alternative” compounds are not susceptible to antimicrobial resistance mechanisms common to traditional antibiotics.

Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, is a fully integrated specialty pharmaceutical company committed to improving the lives of transplant patients. Headquartered in Cary, North Carolina, USA, Veloxis is focused on the global development and commercialization of medications utilized by transplant patients and by patients with serious related diseases. We know what transplant means to patients, and we’re leading innovation to improve their experience. For patients, transplant is a life-changing procedure. But changes come with challenges. At Veloxis, our mission is to see and respond to the challenges along the transplant journey.

vTv Therapeutics is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin, a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv and its development partners are pursuing additional indications, including type 2 diabetes and other chronic conditions.